CD8A and neoplasm: Pre-clinical studies have reported that RT can induce immunogenic cell death, cytokine and chemokine production in the tumor microenvironment, the release of tumor antigens, and release of damage-associated molecular patterns, resulting in a type I interferon response and subsequent anti-tumor CD8+ T cell responses27.